EUCTR2008-003617-27-DE进行中（未招募）1 期
An open phase I/IIa trial to investigate the maximum tolerated dose, safety,pharmacokinetics, and efficacy of intraveneous BI 6727 as monotherapy or in combination with subcutaneous cytarabine in patients with acute myeloid leukaemia
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 143
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Male or female adult with relapsed/refractory AML ineligible for intensive treatment. (phase I part only)
- •Male or female adult with previously untreated (except hydroxyurea) AML ineligible for intensive treatment (phase IIa part only)
- •Confirmed diagnosis of AML according to the WHO definition (except for acute promyelocytic leukaemia, APL)
- •Patient is eligible for LD-Ara-C treatment
- •Life expectancy = 3 months
- •Eastern co-operative oncology group (ECOG, R01-0787) performance score <=2 at screening
- •Signed written informed consent consistent with international conference on harmonisation – good clinical practice (ICH-GCP) and local legislation
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 33
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 110
排除标准
- •Previously untreated AML (phase I part only)
- •Relapsed or treatment refractory AML (phase IIa part only)
- •Patient with APL (AML subtype M3 according to the French-American-British (FAB) classification)
- •Hypersensitivity to one of the trial drugs or the excipients
- •Other malignancy requiring treatment
- •Symptomatic central nervous system involvement
- •Clinically relevant QT prolongation (e.g. long QT syndrome, QTcF > 470 ms)
- •Aspartate amino transferase (AST) or alanine amino transferase (ALT) greater than 2.5 times the upper limit of normal (ULN)
- •Prothrombin time (PT) > 1.5 x ULN for subjects not on therapeutic vitamin K antagonists (phenprocoumon, warfarin)
- •Bilirubin greater than 1.5 mg/dl (> 26 µmol/L)
- •Serum creatinine greater than 2.0 mg/dl
- •Concomitant intercurrent illness, which would compromise the evaluation of efficacy or safety of the trial drug, e.g. active severe infection, unstable angina pectoris, cardiac arrhythmia or severe heart failure/cardiac insufficiency.
- •Psychiatric illness or social situation that would limit compliance with trial requirements
- •Concomitant therapy, which is considered relevant for the evaluation of the efficacy or safety of the trial drug
- •Contraindications for cytarabine treatment according to the SPC
- •Female patients of childbearing potential who are sexually active and unwilling to use a medically acceptable method of contraception during the trial, i.e. combination of two forms of effective contraception (hormonal contraception, intrauterine device, condom with spermicide, etc.). Male patients with partners of childbearing potential who are unwilling to use condoms in combination with a second medically acceptable method of contraception during the trial
- •Pregnant or nursing female patients
- •Patient unable to comply with the protocol
研究者
相似试验
进行中（未招募）
1 期
An phase I/IIa trial to investigate the maximum tolerated dose, safety, pharmacokinetics, and efficacy of intraveneous BI 6727 as monotherapy or in combination with subcutaneous cytarabine in patients with acute myeloid leukaemiapatients with acute myeloid leukaemia (AML) that are not eligible for intensive treatmentMedDRA version: 13.1Level: LLTClassification code 10000886Term: Acute myeloid leukemiaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2008-003617-27-BESCS Boehringer Ingelheim Comm.V143
进行中（未招募）
不适用
An open phase I/IIa trial to investigate the maximum tolerated dose, safety,pharmacokinetics, and efficacy of intraveneous BI 6727 as monotherapy or in combination with subcutaneous cytarabine in patients with acute myeloid leukaemiapatients with acute myeloid leukaemia (AML) that are not eligible for intensive treatmentMedDRA version: 9.1Level: LLTClassification code 10000886Term: Acute myeloid leukemiaEUCTR2008-003617-27-ATBoehringer Ingelheim RCV GmbH & Co. KG143
进行中（未招募）
不适用
An open Phase I/IIa trial to investigate the maximum tolerated dose, safety, efficacy and pharmacokinetics of BI 811283 in combination with cytarabine in patients with previously untreated acute myeloid leukaemia ineligible for intensive treatmentEUCTR2007-005684-10-DEBoehringer Ingelheim Pharma GmbH & Co. KG169
进行中（未招募）
不适用
An open Phase I/IIa trial to investigate the maximum tolerated dose, safety, efficacy and pharmacokinetics of BI 811283 in combination with cytarabine in patients with previously untreated acute myeloid leukaemia ineligible for intensive treatmentPreviously untreated acute myeloid leukaemia in adult patients that are not eligiblefor intensive treatmentMedDRA version: 9.1Level: LLTClassification code 10000886Term: Acute myeloid leukemiaEUCTR2007-005684-10-ATBoehringer Ingelheim RCV GmbH & Co KG169
终止
1 期
This study aims to find and test a safe dose of BI 905677 in patients with different types of cancer (solid tumours)JPRN-jRCT2080224086ippon Boehringer Ingelheim Co., Ltd.37